CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced positive symptom data from its Phase 2 ACeD-it trial evaluating its lead candidate, KAN-101, in individuals with celiac disease. The study data serves as the first symptomatic clinical proof of concept for KAN-101 and its potential as a disease-modifying treatment for celiac disease. KAN-101 ind